ABI-2280
High-risk HPV infection and cervical pre-cancerous lesions
Phase 2Active
Key Facts
Indication
High-risk HPV infection and cervical pre-cancerous lesions
Phase
Phase 2
Status
Active
Company
About Antiva Biosciences
Antiva Biosciences is pioneering a patient-centric, non-surgical approach to treat oncogenic HPV infection and cervical pre-cancer. Its lead candidate, ABI-2280, is a topical therapy designed for at-home use, addressing a significant unmet need where current standards involve invasive procedures or watchful waiting. The company has advanced into Phase 1b/2 clinical trials and is backed by experienced leadership and life science investors. If successful, Antiva's therapy could transform the management of HPV-related disease, improving access and outcomes for women worldwide.
View full company profile